Kiniksa Pharmaceuticals International, plc (KNSA)
KNSANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$95.02
-3.74 (-3.79%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $7.47bn
- P/E
- 73.1
- EPS, last 4 quarters
- $1.30
- Dividend yield
- –
- Day range
- –
- 52-week range
- $37.02 to $99.31
- Average volume
- 713.9k
- Previous close
- $98.76
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $106.20, +11.8% from here
Earnings
next estimate $0.2000Next report
Dec 2025
-41.4%
Mar 2026
+50.0%
Jun 2026
0.0%
Sep 2026
+75.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $202.13m | $214.27m | $243.60m | $285.97m |
| Gross profit | $181.18m | $193.47m | $220.03m | $258.21m |
| Operating income | $19.77m | $29.27m | $27.19m | $54.24m |
| Net income | $14.20m | $22.59m | $25.43m | $47.34m |
Last four quarters: revenue $945.96m, margin 11.6%, free cash flow $197.20m
News
8 latest- Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum StockZacks · 7 days ago
- Kiniksa Pharmaceuticals International Average Price Target Raised 13.15% to $111.62Fintel · Nov 2, 2026
- Show Me The Money: The $100 Club Beckons For Kiniksa Pharma RTTNews · Oct 30, 2026
- Biotech Stocks Move Higher: ZURA Surges 21%, PLUR Gains 13%, WVE Rises 7%, KNSA Advances RTTNews · Oct 27, 2026
- Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Oct 27, 2026
- Kiniksa (KNSA) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 27, 2026
- What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings CallMarketBeat · Oct 27, 2026
- Kiniksa Pharmaceuticals, Ltd. Reports Q3 2026 Net Product Revenue of $286.0 millionFintel · Oct 27, 2026
The company
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa's portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- kiniksa.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.